


In the Claims:

Please cancel claims 33-40. Please amend claims 4-21, 23, 25-26 and 28-32 as follows.

1. (Original) A compound of formula (I):



wherein:

R¹ is selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, -C(O)R⁹, -C(O)Ay, -C(O)Het, -CO₂R⁹, -C(O)NR⁷R⁸, -C(O)NR⁷Ay, -C(S)NR⁹R¹¹, -C(NH)NR⁷R⁸, -C(NH)NR⁷Ay, -OR⁷, -OAY, -OHet, -NR⁷R⁸, -NR⁷Ay, -NHHet, -S(O)_nR⁹, -S(O)_nAy, -S(O)_nHet, -S(O)₂NR⁷R⁸, -S(O)₂NR⁷Ay, -R¹⁰cycloalkyl, -R¹⁰Ay, -R¹⁰Het, -R¹⁰OR⁹, -R¹⁰NR⁷R⁸, -R¹⁰NR⁷Ay, -R¹⁰NHSO₂R⁹, -R¹⁰C(O)R⁹, -R¹⁰C(O)Ay, -R¹⁰C(O)Het, -R¹⁰CO₂R⁹, -R¹⁰OC(O)R⁹, -R¹⁰OC(O)Ay, -R¹⁰OC(O)Het, -R¹⁰C(O)NR⁹R¹¹, -R¹⁰C(O)NR⁷Ay, -R¹⁰C(O)NHR¹⁰Het, -R¹⁰C(S)NR⁹R¹¹, -R¹⁰C(NH)NR⁹R¹¹, -R¹⁰SO₂R⁹, -R¹⁰SO₂NR⁹R¹¹, -R¹⁰SO₂NHCOR⁹, -R¹⁰OS(O)_nR⁹, cyano, nitro and azido;

each R⁷ and R⁸ are the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, -C(O)R⁹, -CO₂R⁹, -C(O)NR⁹R¹¹, -C(S)NR⁹R¹¹, -C(NH)NR⁹R¹¹, -SO₂R¹⁰, -SO₂NR⁹R¹¹, -R¹⁰cycloalkyl, -R¹⁰Ay, -R¹⁰Het, -R¹⁰C(O)R⁹, -R¹⁰CO₂R⁹, -R¹⁰C(O)NR⁹R¹¹, -R¹⁰C(S)NR⁹R¹¹, -R¹⁰OR⁹, -R¹⁰NR⁹R¹¹, -R¹⁰NHCOR⁹, -R¹⁰NHC(NH)NR⁹R¹¹, -R¹⁰C(NH)NR⁹R¹¹, -R¹⁰NHSO₂R⁹, -R¹⁰SO₂NR⁹R¹¹, -R¹⁰SO₂R¹⁰ and -R¹⁰SO₂NHCOR⁹;

each R⁹ and R¹¹ are the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, -R¹⁰cycloalkyl, -R¹⁰OH, -R¹⁰(OR¹⁰)_w where w is 1-10, and



each R^{10} is the same or different and is independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl;

n is 0, 1 or 2;

Ay is aryl;

Het is a 5- or 6-membered heterocyclic or heteroaryl group;

Y^1 is N or CH;

p is 0, 1 or 2 when Y^1 is CH,

p is 0 or 1 when Y^1 is N;

each R^6 is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, $-C(O)R^9$, $-C(O)Ay$, $-C(O)Het$, $-CO_2R^9$, $-C(O)NR^7R^8$, $-C(O)NR^7Ay$, $-C(S)NR^9R^{11}$, $-C(NH)NR^7R^8$, $-C(NH)NR^7Ay$, $-OR^7$, $-OAY$, $-OHet$, $-NR^7R^8$, $-NR^7Ay$, $-NHHet$, $-S(O)_nR^9$, $-S(O)_nAy$, $-S(O)_nHet$, $-S(O)_2NR^7R^8$, $-S(O)_2NR^7Ay$, $-R^{10}cycloalkyl$, $-R^{10}Ay$, $-R^{10}Het$, $-R^{10}OR^9$, $-R^{10}NR^7R^8$, $-R^{10}NR^7Ay$, $-R^{10}NH SO_2R^9$, $-R^{10}C(O)R^9$, $-R^{10}C(O)Ay$, $-R^{10}C(O)Het$, $-R^{10}CO_2R^9$, $-R^{10}OC(O)R^9$, $-R^{10}OC(O)Ay$, $-R^{10}OC(O)Het$, $-R^{10}C(O)NR^9R^{11}$, $-R^{10}C(O)NR^7Ay$, $-R^{10}C(O)NHR^{10}Het$, $-R^{10}C(S)NR^9R^{11}$, $-R^{10}C(NH)NR^9R^{11}$, $-R^{10}SO_2R^9$, $-R^{10}SO_2NR^9R^{11}$, $-R^{10}SO_2NHCOR^9$, $-R^{10}OS(O)_nR^9$, cyano, nitro and azido; or when p is 2, two adjacent R^6 groups together with the carbon atoms to which they are bonded form a cycloalkyl or a 5- or 6-membered heterocyclic group containing 1 or 2 heteroatoms;

Y is N or CH;

R^2 is selected from the group consisting of halo, alkyl, cycloalkyl, alkenyl, cycloalkenyl, Ay, Het, $-OR^7$, $-OAY$, $-OHet$, $-NR^7R^8$, $-NR^7Ay$, $-NHHet$, $-S(O)_nR^9$, $-S(O)_nAy$, $-R^{10}NR^7R^8$ and $-R^{10}NR^7Ay$;

R^3 and R^4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ay, Het, $-C(O)R^7$, $-C(O)Ay$, $-CO_2R^7$, $-CO_2Ay$, $-OR^7$, $-OAY$, $-NR^7R^8$, $-NR^7Ay$, $-NHHet$, $-SO_2NHR^9$, $-R^{10}OR^7$, $-R^{10}cycloalkyl$, $-R^{10}OAY$, $-R^{10}NR^7R^8$ and $-R^{10}NR^7Ay$;

Ring A is selected from the group consisting of aryl, 5-10 membered heterocyclic group and a 5-10 membered heteroaryl group;

q is 0, 1, 2, 3, 4 or 5; and

each R⁵ is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, -C(O)R⁹, -C(O)Ay, -C(O)Het, -CO₂R⁹, -C(O)NR⁷R⁸, -C(O)NR⁷Ay, -C(S)NR⁹R¹¹, -C(NH)NR⁷R⁸, -C(NH)NR⁷Ay, -OR⁷, -OAy, -OHet, -NR⁷R⁸, -NR⁷Ay, -NHHet, -S(O)_nR⁹, -S(O)₂NR⁷R⁸, -S(O)₂NR⁷Ay, -R¹⁰cycloalkyl, -R¹⁰Het, -R¹⁰C(O)R⁹, -R¹⁰CO₂R⁹, -R¹⁰C(O)NR⁹R¹¹, -R¹⁰C(O)NR⁷Ay, -R¹⁰C(O)NHR¹⁰Het, -R¹⁰C(S)NR⁹R¹¹, -R¹⁰C(NH)NR⁹R¹¹, -R¹⁰OR⁹, -R¹⁰NR⁷R⁸, -R¹⁰NR⁷Ay, -R¹⁰SO₂R⁹, -R¹⁰SO₂NR⁹R¹¹, -R¹⁰SO₂NHCOR⁹, cyano, nitro and azido; or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

2. (Original) The compound according to claim 1 wherein R¹ is selected from the group consisting of halo, alkyl, cycloalkyl, Ay, Het, -OR⁷, -OAy, -NR⁷R⁸, -NR⁷Ay, -NHHet, -S(O)_nR⁹, -R¹⁰cycloalkyl, -R¹⁰OR⁹, -R¹⁰NR⁷R⁸ and -R¹⁰NR⁷Ay.

3. (Original) The compound according to claim 1 wherein R¹ is selected from the group consisting of alkyl, Het, -OR⁷, -NR⁷R⁸, -NR⁷Ay and -S(O)_nR⁹.

4. (Currently Amended) The compound according to claim 1 ~~any of claims 1-3~~ wherein Y¹ is CH.

5. (Currently Amended) The compound according to claim 1 ~~any of claims 1-3~~ wherein Y¹ is N.

6. (Currently Amended) The compound according to claim 1 ~~any of claims 1-5~~ wherein p is 0 or 1.

7. (Currently Amended) The compound according to claim 1 ~~any of claims 1-6~~ wherein each R^6 is the same or different and is independently selected from the group consisting of halo, alkyl, Ay, Het, $-C(O)Het$, $-CO_2R^9$, $-C(O)NR^7R^8$, $-C(O)NR^7Ay$, $-OR^7$, $-OAY$, $-NR^7R^8$, $-NR^7Ay$, $-NHHet$, $-S(O)_nR^9$, $-S(O)_nAy$, $-S(O)_nHet$, $-R^{10}OR^9$ and cyano.
8. (Currently Amended) The compound according to claim 1 ~~any of claims 1-6~~ wherein each R^6 is the same or different and is independently selected from the group consisting of halo, alkyl, Het, $-NR^7R^8$, $-NHHet$ and $-S(O)_nR^9$.
9. (Currently Amended) The compound according claim 1 ~~to any of claims 1-8~~ wherein Y is CH.
10. (Currently Amended) The compound according to claim 1 ~~any of claims 1-8~~ wherein Y is N.
11. (Currently Amended) The compound according to claim 1 ~~any of claims 1-10~~ wherein R^2 is selected from the group consisting of Ay, Het, $-OR^7$, $-OAY$, $-OHet$, $-NR^7R^8$, $-NR^7Ay$, $-NHHet$, $-S(O)_nR^9$, $-S(O)_nAy$, $-R^{10}NR^7R^8$ and $-R^{10}NR^7Ay$.
12. (Currently Amended) The compound according to claim 1 ~~any of claims 1-10~~ wherein R^2 is selected from the group consisting of $-NR^7R^8$, $-NR^7Ay$ and $-NHHet$.
13. (Currently Amended) The compound according to claim 1 ~~any of claims 1-12~~ wherein R^3 and R^4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, Ay, $-CO_2R^7$, $-OR^7$, $-NR^7R^8$, $-R^{10}OR^7$ and $-R^{10}NR^7R^8$.
14. (Currently Amended) The compound according to claim 1 ~~any of claims 1-12~~ wherein R^3 and R^4 are both H.

15. (Currently Amended) The compound according to claim 1 ~~any of claims 1-14~~ wherein Ring A is selected from the group consisting of aryl, a 5-6 membered heterocyclic or heteroaryl group and a 9-membered heterocyclic or heteroaryl group.
16. (Currently Amended) The compound according to claim 1 ~~any of claims 1-14~~ wherein Ring A is selected from the group consisting of phenyl, naphthyl, furan, pyridine, pyrimidine, thiazol, pyrazine, pyrrole, imidazole, oxazole, benzimidazole, quinoline, isoquinoline and quinoxoline.
17. (Currently Amended) The compound according to claim 1 ~~any of claims 1-14~~ wherein Ring A is selected from the group consisting of phenyl, furan, pyridine and pyrimidine.
18. (Currently Amended) The compound according to claim 1 ~~any of claims 1-14~~ wherein Ring A is phenyl.
19. (Currently Amended) The compound according to claim 1 ~~any of claims 1-18~~ wherein q is 0, 1 or 2.
20. (Currently Amended) The compound according to claim 1 ~~any of claims 1-19~~ wherein each R⁵ is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, Ay, Het, -CO₂R⁹, -C(O)NR⁷R⁸, -C(O)NR⁷Ay, -OR⁷, -OAY, -NR⁷R⁸, -NR⁷Ay, -S(O)₂NR⁷R⁸, cyano, nitro and azido.
21. (Currently Amended) The compound according to claim 1 ~~any of claims 1-19~~, wherein each R⁵ is the same or different and is independently selected from the group consisting of halo, alkyl, -OR⁷, -NR⁷R⁸ and cyano.
22. (Original) A compound selected from the group consisting of:

N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;
N-Cyclopentyl-3-[2-(cyclopropylamino)pyrimidin-4-yl]-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;
4-[2-(3-Chlorophenyl)pyrazolo[1,5-*c*]pyrimidin-3-yl]-*N*-cyclopentylpyrimidin-2-amine;
4-[2-(3-Chlorophenyl)-7-(methylthio)pyrazolo[1,5-*c*]pyrimidin-3-yl]-*N*-cyclopentylpyrimidin-2-amine;
2-(3-Chlorophenyl)-*N*-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-*c*]pyrimidin-7-amine;
4-[2-(3-Chlorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-*c*]pyrimidin-3-yl]-*N*-cyclopentyl-2-pyrimidinamine;
2-(3-Chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-*N*-(2-methoxyethyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;
2-(3-Chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-*c*]pyrimidin-7-ol;
N-Cyclopentyl-8-(2-fluoro-4-pyridinyl)-2-(methylsulfanyl)-7-phenylpyrazolo[1,5-*a*][1,3,5]triazin-4-amine;
*N*²,*N*⁴-Dicyclopentyl-8-[2-(cyclopentylamino)-4-pyridinyl]-7-phenylpyrazolo[1,5-*a*][1,3,5]triazine-2,4-diamine;
N-Cyclopentyl-8-[2-(cyclopentylamino)-4-pyrimidinyl]-7-phenylpyrazolo[1,5-*a*][1,3,5]triazin-4-amine;
3-[2-(Butylamino)pyrimidin-4-yl]-*N*-cyclopentyl-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;
3-(2-Anilinopyrimidin-4-yl)-*N*-cyclopentyl-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;
3-[2-(1,3-Benzothiazol-2-ylamino)pyrimidin-4-yl]-*N*-cyclopentyl-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;
N-Cyclopentyl-2-(4-fluorophenyl)-3-{2-[(4-methyl-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}pyrazolo[1,5-*c*]pyrimidin-7-amine;
3-[2-(1*H*-Benzimidazol-2-ylamino)pyrimidin-4-yl]-*N*-cyclopentyl-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;

N-Cyclopentyl-3-{2-[(4-fluorobenzyl)amino]pyrimidin-4-yl}-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;
N-Cyclopentyl-2-(4-fluorophenyl)-3-{2-[(2-phenylethyl)amino]pyrimidin-4-yl}pyrazolo[1,5-*c*]pyrimidin-7-amine;
3-[2-(*tert*-Butylamino)pyrimidin-4-yl]-*N*-cyclopentyl-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;
N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(methylsulfanyl)pyrazolo[1,5-*c*]pyrimidin-3-yl]pyrimidin-2-amine;
N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;
4-{7-(Cyclopentylamino)-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-*c*]pyrimidin-2-yl}phenol;
3-[2-(Cyclopentylamino)pyrimidin-4-yl]-*N*-cyclopropyl-2-(4-methoxyphenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;
2-(4-Butoxyphenyl)-*N*-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]pyrazolo[1,5-*c*]pyrimidin-7-amine;
N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-isobutoxyphenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;
N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-[4-(2-methoxyethoxy)phenyl]pyrazolo[1,5-*c*]pyrimidin-7-amine;
N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-propoxyphenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;
N-(*tert*-Butyl)-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(4-fluorophenyl)pyrazolo[1,5-*c*]pyrimidin-7-amine;
N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-pyrrolidin-1-ylpyrazolo[1,5-*c*]pyrimidin-3-yl]pyrimidin-2-amine; and
N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-piperidin-1-ylpyrazolo[1,5-*c*]pyrimidin-3-yl]pyrimidin-2-amine, or
a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

23. (Currently Amended) A pharmaceutical composition comprising a compound according to claim 1 ~~any of claims 1-22~~.

24. (Original) The pharmaceutical composition according to claim 23 further comprising a pharmaceutically acceptable carrier or diluent.


25. (Currently Amended) The pharmaceutical composition according to claim 23 ~~any of claims 23-24~~ further comprising an antiviral agent selected from the group consisting of aciclovir and valaciclovir.

26. (Currently Amended) A method for the prophylaxis or treatment of a herpes viral infection in an animal, said method comprising administering to the animal a therapeutically effective amount of a compound according to claim 1 ~~any of claims 1-22~~.


27. (Original) The method according to claim 26 wherein said herpes viral infection is selected from the group consisting of herpes simplex virus 1, herpes simplex virus 2, cytomegalovirus, Epstein Barr virus, varicella zoster virus, human herpes virus 6, human herpes virus 7 and human herpes virus 8.

28. (Currently Amended) A method for the prophylaxis or treatment of a condition or disease associated with a herpes viral infection in an animal, comprising administering to the animal a therapeutically effective amount of the compound of formula (I) according to claim 1 ~~any of claims 1-22~~.


29. (Currently Amended) A process for preparing a compound according to any claim 1 ~~of claims 1-22~~ wherein Y^1 is CH; Y is N; R^2 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, Ay, Het, $-OR^7$, $-OAY$, $-OHet$, $-NR^7R^8$, $-NR^7AY$, $-NHHet$, $-S(O)_nR^9$, $-S(O)_nAY$, $-R^{10}NR^7R^8$ and $-R^{10}NR^7AY$; and R^3 and R^4 are H, said process comprising reacting a compound of formula (XX):




with a compound of formula (XXI):



30. (Currently Amended) A process for preparing a compound according to claim 1 ~~any of claims 1-22~~ wherein Y is N; R² is selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, Ay, Het, -OR⁷, -OAY, -OHet -NR⁷R⁸, -NR⁷AY, -NHHet -S(O)_nR⁹, -S(O)_nAY, -R¹⁰NR⁷R⁸ and -R¹⁰NR⁷AY; R³ is selected from the group consisting of H, alkyl, alkenyl, cycloalkyl, Ay, Het, -C(O)R⁷, C(O)AY, -CO₂R⁷, -CO₂AY, -OR⁷, -OAY, -NR⁷R⁸ (where R⁷ and R⁸ are not H), -NR⁷AY (where R⁷ is H), -SO₂NHR⁹, -R¹⁰OR⁷, -R¹⁰cycloalkyl, -R¹⁰OAY, -R¹⁰NR⁷R⁸ and -R¹⁰NR⁷AY; and R⁴ is H said process comprising reacting a compound of formula (XXV):




with a compound of formula (XXI):




31. (Currently Amended) A process for preparing a compound according to claim 1 ~~any of claims 1-22~~ wherein Y is N and R² is selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, Ay, Het, -OR⁷,

-OAy, -OHet -NR⁷R⁸, -NR⁷Ay, -NHHet -S(O)_nR⁹, -S(O)_nAy, -R¹⁰NR⁷R⁸ and -R¹⁰NR⁷Ay, said process comprising the steps of:

a) reacting a compound of formula (XXVIII):




with a compound of formula (XXI):



to prepare an intermediate compound; and


b) oxidizing the intermediate compound.

32. (Currently Amended) A process for preparing a compound according to claim 1 ~~any of claims 1-22~~ comprising reacting a compound of formula (XXX):



wherein X¹ is chloro, bromo or iodo;

with a compound of formula (X):



wherein M¹ is -B(OH)₂, -B(ORa)₂, -B(Ra)₂, -Sn(Ra)₃, Zn-halide, ZnRa, or Mg-halide where Ra is alkyl or cycloalkyl and halide is halo.

33-40. (Canceled)